A Billion-Dollar Effort to Make Medicine Move Faster
The most intriguing AI trade in medicine may not be a machine that replaces a scientist. It may be a scientist who can finally stop waiting on the machine. Eli Lilly and Company (NYSE:…
A Precision-Oncology Bet With Room to Grow
Eli Lilly and Company (NYSE: LLY) is adding another potential growth engine to a business already well acquainted with acceleration. On November 16, Calytrix Bio announced a definitive agreement to be acquired by Lilly in…
Takeover premiums, stronger earnings and resilient drug demand give Wall Street fresh reasons to look beyond the market’s familiar favorites.
Wall Street’s most encouraging stories do not always arrive wearing the same uniform. On October 29, they came dressed as a home-security…
Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…
